Noopept
The Dipeptide Nootropic
Molecular Data
- Formula
- C17H22N2O4
- Molecular Weight
- 318.37 g/mol
01
Overview
Noopept (N-phenylacetyl-L-prolylglycine ethyl ester) is a synthetic dipeptide-derived compound with potent nootropic properties, originally developed in Russia. It is a prodrug of cycloprolylglycine and demonstrates rapid CNS penetration. Research shows neuroprotective, neuroplastic, and cognitive-enhancing activity at very low doses.
02
Mechanism of Action
Noopept is hydrolyzed to cycloprolylglycine (CPG) and phenylacetic acid in vivo. CPG modulates AMPA and NMDA receptor function, enhancing synaptic plasticity. It also increases acetylcholine levels in the cerebral cortex and hippocampus and stimulates NGF/BDNF expression.
03
Research Highlights
Russian clinical trials show cognitive improvement in patients with mild cognitive disorders
Neuroprotection studies show protection against beta-amyloid toxicity in Alzheimer's models
EEG studies show increased alpha and beta wave activity associated with improved focus
04
Dosage
Administration & Timing
Oral administration (capsule or solution), typically twice daily with meals to improve absorption. Approved in Russia as a nootropic.
Dosage Guidelines
Cycle Length
4–8 weeks; followed by 1–3 month rest period in long-term research.
05
Reconstitution
Solvent
Not applicable — orally dosed capsule or tablet
Volume
N/A
Concentration
10 mg per unit dose
Storage
Store at room temperature (15–25 °C); protect from moisture and light.
Notes
Noopept has high oral bioavailability (~90%) and is metabolized to cycloprolylglycine. No reconstitution required.
Research Reference Only
Dosage and reconstitution values reflect commonly cited ranges from published research literature and are presented for educational and research reference only. This is not medical advice or a dosing recommendation. HEXAGEN does not endorse human use of any compound. Always consult a qualified healthcare professional.
Research Disclaimer
Noopept is for educational and research purposes only. Not intended as medical advice. Consult a qualified healthcare professional before making any health-related decisions.
Related Compounds
View All
Noopept Knowledge Graph
Explore how Noopept connects to mechanisms, research goals, related compounds, research stacks, and scientific references. Drag nodes, zoom, and filter by type.
No nodes match the active filters.
Noopept — Common Research Questions
What is Noopept?
Noopept (N-phenylacetyl-L-prolylglycine ethyl ester) is a synthetic dipeptide-derived compound with potent nootropic properties, originally developed in Russia. It is a prodrug of cycloprolylglycine a... Noopept belongs to the Cognitive research category and is studied for its the dipeptide nootropic.
How does Noopept work?
Noopept is hydrolyzed to cycloprolylglycine (CPG) and phenylacetic acid in vivo. CPG modulates AMPA and NMDA receptor function, enhancing synaptic plasticity. It also increases acetylcholine levels in the cerebral cortex and hippocampus and stimulates NGF/BDNF expression.
What are the key research benefits of Noopept?
Enhanced memory encoding and retrieval. Neuroprotection against oxidative and excitotoxic damage. BDNF and NGF upregulation. Improved interhemispheric communication. Anxiolytic effects at higher doses. Psychostimulant-free cognitive enhancement.
What is the molecular structure of Noopept?
Noopept has the molecular formula C17H22N2O4 and a molecular weight of 318.37 g/mol. This structural information is important for researchers studying receptor binding and pharmacokinetics.
What does the research say about Noopept?
Russian clinical trials show cognitive improvement in patients with mild cognitive disorders Neuroprotection studies show protection against beta-amyloid toxicity in Alzheimer's models EEG studies show increased alpha and beta wave activity associated with improved focus These findings are based on preclinical and clinical research. Noopept is a research compound and these studies do not constitute medical advice.
Is Noopept FDA approved?
No. Noopept is not FDA-approved for any indication. It is a research chemical studied in preclinical and early clinical research. These compounds are not approved for human therapeutic use and should only be studied in appropriate research settings.
What category does Noopept belong to?
Noopept belongs to the Cognitive category, which focuses on peptides investigated for their nootropic and neuroprotective potential, supporting mental clarity, memory consolidation, and neurological resilience. You can explore more compounds in this category on the Cognitive pillar page.
Related Articles
Semax: BDNF Upregulation and Cognitive Enhancement
A review of Semax's mechanism — from melanocortin receptor modulation to BDNF and NGF upregulation in the hippocampus.
Dihexa: Synaptogenesis and Spatial Memory
Washington State University research on Dihexa's dramatic effects on synaptogenesis and Morris water maze performance.
Noopept: The Dipeptide Nootropic
Understanding Noopept's prodrug conversion, BDNF/NGF upregulation, and its position as a dipeptide nootropic.
Scientific References
Ostrovskaya et al. — "Noopept: dipeptide nootropic" (Acta Naturae, 2014)
Gudasheva — Prodrug conversion and BDNF/NGF upregulation, Bull Exp Biol Med, 2011
Russian clinical trials show cognitive improvement in patients with mild cognitive disorders
Neuroprotection studies show protection against beta-amyloid toxicity in Alzheimer's models
EEG studies show increased alpha and beta wave activity associated with improved focus